ReviewGut pathogens2026
Fungi and colorectal cancer: from dysregulation to clinical translation.
Review in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Research on the gut microbiota has primarily focused on bacterial communities. However, the role of fungi-the second-largest eukaryotic component of the gut microbiome-in the development and progression of colorectal cancer (CRC) has been less extensively studied compared to bacteria. Recent studies have revealed significant fungal dysbiosis in the intestines of CRC patients, where the enrichment of specific pathogenic fungi (e.g., Aspergillus spp.) is closely associated with tumor progression, while the reduction of certain commensal fungi may weaken their protective effects. This fungal imbalance not only directly promotes tumorigenesis through carcinogenic mechanisms but also indirectly accelerates CRC progression by reshaping the bacteria-fungi interaction network and the host immune microenvironment. This article reviews the structural alterations of fungal communities in CRC, the changing patterns of specific fungal species, the relationship between fungal dysbiosis and clinicopathological features, the potential molecular mechanisms of fungi in CRC pathogenesis, the significance of cross-kingdom microbial interactions, as well as the potential diagnostic and therapeutic applications of fungi in CRC and the challenges and prospects of novel fungal-modulating therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.